Literature DB >> 986285

Enhancement of alcohol withdrawal convulsions in mice by haloperidol.

K Blum, J D Eubanks, J E Wallace, H Hamilton.   

Abstract

Based on the data presented here and the clinical observations cited it would appear that although haloperidol has been used with a certain degree of success for the treatment of acute alcohol abstinence the authors would like to caution the clinician against widespread use of heloperidol for treatment of alcohol withdrawal. In experimentally induced ethanol withdrawal, chlordiazepoxide appears to be a more effective and safer agent for ameliorating symptoms associated with excitation such as tremor, insomnia, anxiety, and hyperexcitability. A double blind comparative clinical investigation between chlordiazepoxide and haloperidol for treatment of alcohol withdrawal is warranted.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 986285     DOI: 10.3109/15563657608988141

Source DB:  PubMed          Journal:  Clin Toxicol        ISSN: 0009-9309            Impact factor:   4.467


  5 in total

Review 1.  Acute poisoning: understanding 90% of cases in a nutshell.

Authors:  S L Greene; P I Dargan; A L Jones
Journal:  Postgrad Med J       Date:  2005-04       Impact factor: 2.401

2.  A strategy of escalating doses of benzodiazepines and phenobarbital administration reduces the need for mechanical ventilation in delirium tremens.

Authors:  Jeffrey A Gold; Binaya Rimal; Anna Nolan; Lewis S Nelson
Journal:  Crit Care Med       Date:  2007-03       Impact factor: 7.598

3.  The role of a medical toxicologist for assistance in the treatment of alcohol withdrawal syndrome.

Authors: 
Journal:  J Med Toxicol       Date:  2012-06

Review 4.  Managing alcohol withdrawal in the elderly.

Authors:  K L Kraemer; J Conigliaro; R Saitz
Journal:  Drugs Aging       Date:  1999-06       Impact factor: 3.923

Review 5.  Animal models of drug withdrawal symptoms.

Authors:  M W Emmett-Oglesby; D A Mathis; R T Moon; H Lal
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.